Status:
COMPLETED
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
Lead Sponsor:
Thomas Jefferson University
Conditions:
Acquired Immunodeficiency Syndrome
Anemia
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To determine whether administration of human recombinant erythropoietin (REPO) improved or eliminated the anemia seen in human immunodeficiency virus (HIV) infected patients after therapy with zidovud...
Detailed Description
BACKGROUND: Reports had shown that between 24 and 78 percent of patients with Acquired Immune Deficiency Syndrome treated with zidovudine for four to six months developed significant bone marrow toxi...
Eligibility Criteria
No eligibility criteria
Key Trial Info
Start Date :
September 1 1988
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000587
Start Date
September 1 1988
End Date
January 1 2005
Last Update
November 26 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.